Director John Travaglini reports as Lixte (LIXT) insider with no trades

Rhea-AI Filing Summary

LIXTE Biotechnology Holdings filed an initial insider ownership report for director John Francis Travaglini. This Form 3 identifies him as a director, not an officer or 10% owner. The data provided shows no reported transactions or existing derivative positions at this time.

Key Terms

Form 3, reportingPersons, director

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [ { "name": "Travaglini John Francis""

director financial

""is_director": 1"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/02/2026 - 12:52 PM Accepted by SEC EDGAR 07/02/2026 - 12:51 PM Learn about SEC filing dates

FAQ

What does John Francis Travaglini’s Form 3 for LIXT report?

The Form 3 identifies John Francis Travaglini as a director of LIXTE Biotechnology Holdings. It serves as his initial beneficial ownership report and, in this data, shows no stock transactions or derivative positions.

Is John Francis Travaglini a 10% owner of LIXTE (LIXT) according to this filing?

No. The filing flags that John Francis Travaglini is a director but not a 10% owner of LIXTE Biotechnology Holdings. It classifies him solely based on his board role, with no indication of large ownership in this excerpt.

Does the LIXTE (LIXT) Form 3 show any stock purchases or sales by John Travaglini?

No transactions are shown. The insider data list zero buy, sell, acquire, or dispose events for John Francis Travaglini. This Form 3 functions as an initial ownership report rather than a record of trades.

Are there any derivative securities reported for John Travaglini in the LIXTE Form 3?

No. The derivativeSummary section is empty, indicating no options, warrants, or other derivatives reported for John Francis Travaglini in this Form 3 excerpt for LIXTE Biotechnology Holdings.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Travaglini John Francis

(Last) (First) (Middle)

433 PLAZA REAL, SUITE 275

(Street)

BOCA RATON FLORIDA 33432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2026

3. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ John Travaglini	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)